CD38 and Miyoshi myopathy: Of note, according to published data IMiDs, such as lenalidomide and pomalidomide may enhance the expression of cell surface CD38 on Tregs of patients with MM, conferring further sensitivity to CD38 MoAbs treatment [118]; moreover, the concomitant administration of MoAbs that target CD38 with IMiDs further enhances NK- and CD8+ T-effector cell-mediated antitumor immune responses and antibody-dependent cell-mediated cytotoxicity (ADCC), strengthening thus antimyeloma activity [120].